Welcome to our dedicated page for American Vanguard SEC filings (Ticker: AVD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Looking for the latest on American Vanguard’s crop-protection pipeline, EPA approvals, or executive stock sales? This page gathers every SEC disclosure—from the annual report 10-K that details pesticide registration assets to the 8-K material events that announce product recalls—so you can follow each development without wading through dense legal text.
Our platform adds context investors routinely search for, including:
- AI-powered summaries that translate technical chemistry jargon into plain language, making American Vanguard SEC filings explained simply.
- Real-time Form 4 alerts to monitor American Vanguard insider trading Form 4 transactions and spot buying or selling trends before the market reacts.
- Instant access to every American Vanguard quarterly earnings report 10-Q filing with side-by-side AI analysis of seasonality, raw-material costs, and margin shifts.
Whether you’re comparing segment performance across soil fumigants, herbicides, and insecticides, or checking the proxy statement executive compensation for incentive metrics tied to new product launches, Stock Titan surfaces what matters. Our expert models flag environmental remediation reserves, goodwill tied to pesticide registrations, and supply-chain risk disclosures buried deep in the footnotes—saving hours of manual review.
Bookmark this hub to track American Vanguard executive stock transactions Form 4, receive AI highlights of each earnings report filing analysis, and get every filing—10-K, 10-Q, 8-K, S-8—delivered moments after it hits EDGAR. Understanding American Vanguard’s SEC documents with AI has never been this straightforward.
Mark R. Bassett, a director of American Vanguard Corporation (AVD), reported the award of 17,621 deferred stock units (DSUs) on 08/07/2025 as part of the company’s non-management director compensation program. The DSUs are granted at $0, are nontransferable during the recipient’s service, and represent the right to receive one share of common stock upon settlement when the recipient’s service ends.
Following the award, the form shows 34,411 shares/units beneficially owned by the reporting person. No derivative securities were reported and the filing was submitted as an individual Form 4 by the director.
Carmen Tiu de Mino, a director of American Vanguard Corporation (AVD), was awarded 17,621 deferred stock units on 08/07/2025 as part of the company's non-management director compensation program. Each deferred stock unit (DSU) entitles the holder to one share upon settlement when the recipient's service with the company ends; DSUs are nontransferable and carry neither voting nor dividend rights during the remaining term of service.
Following the award, the reporting person beneficially owned 24,407 shares on a direct basis. The DSUs were issued at a recorded price of $0 and are subject to the company's standard DSU agreement.
Marisol Angelini, a director of American Vanguard Corp (AVD), reported on Form 4 that she was awarded 17,621 shares of common stock on 08/07/2025 as part of the companys compensation program for non-management directors related to the 2025 annual stockholders meeting. The award is reported at a price of $0 in the filing and is explained in an accompanying footnote.
Following the award, Angelini beneficially owns 36,890 shares. The Form 4 was signed on 08/08/2025 and filed by one reporting person. No derivative transactions are listed in Table II.
Gunter Emer, a director of American Vanguard Corporation (AVD), reported receiving 8,810 shares of common stock on 08/07/2025 as part of the company’s non-management director compensation program. The award was issued at $0 and increased his direct beneficial ownership to 33,723 shares.
The Form 4 shows no derivative securities and records the filing signature on 08/08/2025. The disclosure reflects a routine director equity award tied to the 2025 annual stockholders’ meeting rather than a market purchase or sale.
American Vanguard Corporation director Steven D. Macicek was awarded 17,621 deferred stock units (DSUs) on 08/07/2025 as part of the companys non-management director compensation program tied to the 2025 annual stockholders meeting. Each DSU represents the right to receive one share of common stock upon settlement.
The DSUs were granted at $0, are nontransferable during the recipients service, and carry no voting or dividend rights until settlement. Following the award the reporting persons beneficial ownership is reported as 48,839 shares.
American Vanguard Corporation (AVD) reported that director Scott Baskin was awarded 8,810 shares of common stock on 08/07/2025 as part of the company’s non-management director compensation program. The shares were granted at a price of $0, reflecting an award rather than an open-market purchase.
Following the grant, Mr. Baskin’s reported beneficial ownership increased to 41,997 shares. The filing identifies Mr. Baskin as a director and notes the award was connected to the 2025 annual stockholders' meeting. This is a routine equity award disclosed on Form 4 and does not include additional transactions or derivative positions.
Patrick E. Gottschalk, a director of American Vanguard Corporation (AVD), was awarded 17,621 deferred stock units (DSUs) on 08/07/2025 as part of the companys non-management director compensation program. Each DSU represents the right to receive one share of common stock upon settlement when the recipients service with the company ends; while outstanding the DSUs are nontransferable and carry neither voting nor dividend rights.
Following the award, Gottschalks reported beneficial ownership of AVD common stock is 79,424 shares (direct). The DSUs were granted at a reported price of $0 and are subject to the companys standard DSU agreement.
American Vanguard (AVD) Q2-25 10-Q highlights:
- Net sales grew 1% YoY to $129.3 m; U.S. crop +1%, U.S. non-crop +3%, International flat.
- Cost-of-sales fell 2%, lifting gross margin to 31% (29% LY). Gross profit +7% to $40.5 m.
- Operating expenses -23% to $36.2 m as transformation spending fell to $1.6 m (vs $7.3 m). Operating income swung to $4.4 m (-$9.2 m).
- After $4.5 m net interest and $0.8 m tax expense, quarterly net loss narrowed sharply to $0.8 m (-$11.7 m); EPS -$0.03.
- 1H-25: revenue -7% to $245.1 m; gross margin 29% (30% LY); operating break-even ($0.1 m); net loss $9.3 m vs -$10.2 m.
- Cash used in operations -$39.8 m (vs -$49.4 m LY) driven by $46.2 m drawdown of customer prepayments and $9.8 m inventory build.
- Debt climbed to $189.5 m (12/24: $147.3 m); average borrowing rate 8.4% Q2.
- May-25 Eleventh Amendment cut revolver to $245 m and suspended leverage & FCCR covenants through 2025, adding minimum liquidity & EBITDA tests. Company had $31.8 m available capacity at 6-30-25.
- No dividends permitted under amended facility.
- Material weaknesses in ICFR (Australia, close process, risk assessment) persist.
- Legal exposure: out-of-spec insecticide lots may create material claims; loss not yet estimable.
Management sees early ag-market recovery, expects lower transformation spend and continues talks to extend credit facility (matures Aug-26).
FAQ
What is the current stock price of American Vanguard (AVD)?
What is the market cap of American Vanguard (AVD)?
